Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B.
Ferla R, Dell'Aquila F, Doria M, Ferraiuolo M, Noto A, Grazioli F, Ammendola V, Testa F, Melillo P, Iodice C, Risca G, Tedesco N, le Brun PR, Surace EM, Simonelli F, Galimberti S, Valsecchi MG, Marteau JB, Veron P, Colloca S, Auricchio A. Ferla R, et al. Among authors: colloca s. Mol Ther Methods Clin Dev. 2023 Feb 11;28:396-411. doi: 10.1016/j.omtm.2023.02.002. eCollection 2023 Mar 9. Mol Ther Methods Clin Dev. 2023. PMID: 36910588 Free PMC article.
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.
Bartolomeo R, Troise F, Allocca S, Sdruscia G, Vitale R, Bignone V, Petrone AM, Romano G, D'Alise AM, Ruzza V, Garzia I, Leoni G, Merone R, Lanzaro F, Colloca S, Siani L, Scarselli E, Cotugno G. Bartolomeo R, et al. Among authors: colloca s. Vaccines (Basel). 2024 Mar 19;12(3):325. doi: 10.3390/vaccines12030325. Vaccines (Basel). 2024. PMID: 38543959 Free PMC article.
Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates.
Moliva JI, Andrew SF, Flynn BJ, Wagner DA, Foulds KE, Gagne M, Flebbe DR, Lamb E, Provost S, Marquez J, Mychalowych A, Lorag CG, Honeycutt CC, Burnett MR, McCormick L, Henry AR, Godbole S, Davis-Gardner ME, Minai M, Bock KW, Nagata BM, Todd JM, McCarthy E, Dodson A, Kouneski K, Cook A, Pessaint L, Ry AV, Valentin D, Young S, Littman Y, Boon ACM, Suthar MS, Lewis MG, Andersen H, Alves DA, Woodward R, Leuzzi A, Vitelli A, Colloca S, Folgori A, Raggiolli A, Capone S, Nason MC, Douek DC, Roederer M, Seder RA, Sullivan NJ. Moliva JI, et al. Among authors: colloca s. bioRxiv [Preprint]. 2023 Nov 22:2023.11.22.567930. doi: 10.1101/2023.11.22.567930. bioRxiv. 2023. PMID: 38076895 Free PMC article. Preprint.
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R; COVITAR study group. Capone S, et al. Among authors: colloca s. Cell Rep Med. 2023 Jun 20;4(6):101084. doi: 10.1016/j.xcrm.2023.101084. Epub 2023 May 29. Cell Rep Med. 2023. PMID: 37315558 Free PMC article. Clinical Trial.
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
Agrati C, Castilletti C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordi L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastri E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Agrati C, et al. Among authors: colloca s. NPJ Vaccines. 2022 Sep 24;7(1):111. doi: 10.1038/s41541-022-00531-8. NPJ Vaccines. 2022. PMID: 36153335 Free PMC article.
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.
Lanini S, Capone S, Antinori A, Milleri S, Nicastri E, Camerini R, Agrati C, Castilletti C, Mori F, Sacchi A, Matusali G, Gagliardini R, Ammendola V, Cimini E, Grazioli F, Scorzolini L, Napolitano F, Plazzi MM, Soriani M, De Luca A, Battella S, Sommella A, Contino AM, Barra F, Gentile M, Raggioli A, Shi Y, Girardi E, Maeurer M, Capobianchi MR, Vaia F, Piacentini M, Kroemer G, Vitelli A, Colloca S, Folgori A, Ippolito G. Lanini S, et al. Among authors: colloca s. Sci Transl Med. 2022 Jan 12;14(627):eabj1996. doi: 10.1126/scitranslmed.abj1996. Epub 2022 Jan 12. Sci Transl Med. 2022. PMID: 34698501 Free article.
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
Capone S, Raggioli A, Gentile M, Battella S, Lahm A, Sommella A, Contino AM, Urbanowicz RA, Scala R, Barra F, Leuzzi A, Lilli E, Miselli G, Noto A, Ferraiuolo M, Talotta F, Tsoleridis T, Castilletti C, Matusali G, Colavita F, Lapa D, Meschi S, Capobianchi M, Soriani M, Folgori A, Ball JK, Colloca S, Vitelli A. Capone S, et al. Among authors: colloca s. Mol Ther. 2021 Aug 4;29(8):2412-2423. doi: 10.1016/j.ymthe.2021.04.022. Epub 2021 Apr 23. Mol Ther. 2021. PMID: 33895322 Free PMC article.
Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.
Napolitano F, Merone R, Abbate A, Ammendola V, Horncastle E, Lanzaro F, Esposito M, Contino AM, Sbrocchi R, Sommella A, Duncan JD, Hinds J, Urbanowicz RA, Lahm A, Colloca S, Folgori A, Ball JK, Nicosia A, Wizel B, Capone S, Vitelli A. Napolitano F, et al. Among authors: colloca s. PLoS Negl Trop Dis. 2021 Apr 13;15(4):e0009348. doi: 10.1371/journal.pntd.0009348. eCollection 2021 Apr. PLoS Negl Trop Dis. 2021. PMID: 33848297 Free PMC article.
79 results